Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gemphire Therapeutics Inc    GEMP

GEMPHIRE THERAPEUTICS INC (GEMP)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 12/14 09:59:51 pm
0.8999 USD   -0.01%
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Gemphire Therapeutics : Shares Fall Over 50% in Heavy Trading -- Market Mover

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/10/2018 | 05:19pm CET

Gemphire Therapeutics Inc. (GEMP) saw its shares drop by over 50% in Friday trading, after the company announced the termination of a clinical trial of gemcabene. At 10:51 a.m. EDT, Gemphire shares had fallen to $1.38, down 57.80%, in heavy trading. Earlier in the week, the company announced it amended an agreement with Pfizer, Inc. concerning gemcabene. Shares opened the trading week at $7.55, and have been paused several times on Friday due to trading volatility. (stephen.nakrosis@wsj.com)

Stocks mentioned in the article
ChangeLast1st jan.
GEMPHIRE THERAPEUTICS INC -0.01% 0.8999 Delayed Quote.-88.67%
PFIZER -1.73% 43.8 Delayed Quote.23.05%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GEMPHIRE THERAPEUTICS INC
12/04GEMPHIRE THERAPEUTICS : Announces Review of Strategic Alternatives and Provides ..
AQ
12/03GEMPHIRE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (fo..
AQ
12/03GEMPHIRE THERAPEUTICS : Announces Review of Strategic Alternatives and Provides ..
AQ
11/08GEMPHIRE THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
11/08GEMPHIRE THERAPEUTICS INC. : Results of Operations and Financial Condition, Fina..
AQ
11/08Gemphire Therapeutics Reports Third Quarter 2018 Financial Results and Provid..
GL
09/26GEMPHIRE THERAPEUTICS : Announces Workforce Reduction
AQ
09/26BIOCENTURY - MANAGEMENT TRACKS : Curis, Gemphire
AQ
09/24Gemphire Therapeutics Announces Workforce Reduction
GL
09/24GEMPHIRE THERAPEUTICS INC. : Costs Associated with Exit or Disposal Activities, ..
AQ
More news
Financials ($)
Sales 2018 -
EBIT 2018 -25,4 M
Net income 2018 -26,0 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 0
Capi. / Sales 2019 0
Capitalization 12,8 M
Chart GEMPHIRE THERAPEUTICS INC
Duration : Period :
Gemphire Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GEMPHIRE THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 3,33 $
Spread / Average Target 270%
EPS Revisions
Managers
NameTitle
Steven R. Gullans President, CEO, CFO, CAO & Director
Charles L. Bisgaier Chairman & Chief Scientific Officer
P. Kent Hawryluk Independent Director
Kenneth Kousky Independent Director
Pedro Lichtinger Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GEMPHIRE THERAPEUTICS INC-88.67%13
GILEAD SCIENCES-8.47%84 823
VERTEX PHARMACEUTICALS15.72%43 460
REGENERON PHARMACEUTICALS1.39%40 527
GENMAB3.84%9 952
SAREPTA THERAPEUTICS INC114.81%7 987